// App-Quantinova.ai

437 : OPTIMAL DURATION OF DUAL ANTIPLATELET THERAPY AFTER DES IMPLANTATION: EXCELLENT TRIAL AND FUTURE PERSPECTIVES

Researchers

Presenter

  • Francesco Costa

Principal Investigators

  • Marco Valgimigli

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Acute Coronary Syndromes

  • Venous thrombosis

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Acetyl-CoA carboxylase

Drug/Treatment

  • ZoMaxx

  • Clopidogrel bisulfate

  • Aspirin

  • Albyl-E

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved